UV LED Phototherapy
Systems
Technology
Applications
Research
News
Partnering
Management
Contact
News
Latest News Release: July 31, 2009, Albany, NY
TanThera, Inc. ("TanThera") is announcing the receipt of U.S. Food & Drug Administration ("FDA") letter dated May 29, 2009 indicating a clearance for the TanThera-T35 UVA1 Light Emitting Diode Tanning Chamber Section 510(k) premarket notification application stating "Indications for Use: Intended to provide ultraviolet light to tan the skin."
The TanThera-T35 is TanThera's flagship LED Tanning bed design, which would be produced in limited quantities for evaluation by qualified customers only. TanThera believes that it has advanced the state-of-the-art in tanning devices by incorporating UVA1 LEDs that are optimized for tanning without producing the UVC, UVB, or UVA2 spectral lines emitted by mercury-vapor tanning lamps commonly used in other tanning devices. UVA1 is closer to blue light, whereas UVA2 is closer to UVB. Since UVA1 is less energetic than UVA2, UVA1 is thought to be less damaging than UVA2, UVB and UVC.
TanThera intends to promote the use of more precise terms to reduce the confusion surrounding ultraviolet light caused by the broad definition of the terms UVC, UVB, and UVA, which have varied in the scientific literature. Within a single range, the effects of different wavelengths can be vastly different, which causes additional confusion. The confusion resulting from the blurring of the specific wavelengths has created on-going debates over health benefits and risks associated with ultraviolet light. TanThera believes that much of the conflicting advice related to ultraviolet light would be resolved if the terms UVC, UVB, and UVA were abandoned in favor of more accurate descriptors.
The term UVC is defined herein as light from 100 nanometer ("nm") to 280 nm. The term UVB is defined herein as light from 280 nm to 320 nm. The term UVA is defined herein as light from 320 nm to 400 nm. UVA is often sub-divided into UVA1 and UVA2. The term UVA1 is defined herein as light with wavelengths from 340 nm to 400 nm. The term UVA2 is defined herein as light with wavelengths from 320 nm to 340 nm.
TanThera is a New York state corporation which has a mission to commercialize UV LED tanning products and services. TanThera is a wholly owned subsidiary of Opthera, Inc., also a New York state corporation, with a mission to commercialize UV LED tanning and phototherapy products and services.
For more information contact:
Peter Fiset, CEO Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211 USA
email: PeterFiset@Opthera.com
News Release: November 6th, 2008, Albany, NY.
Latest News Release: July 31, 2009, Albany, NY
TanThera, Inc. ("TanThera") is announcing the receipt of U.S. Food & Drug Administration ("FDA") letter dated May 29, 2009 indicating a clearance for the TanThera-T35 UVA1 Light Emitting Diode Tanning Chamber Section 510(k) premarket notification application stating "Indications for Use: Intended to provide ultraviolet light to tan the skin."
The TanThera-T35 is TanThera's flagship LED Tanning bed design, which would be produced in limited quantities for evaluation by qualified customers only. TanThera believes that it has advanced the state-of-the-art in tanning devices by incorporating UVA1 LEDs that are optimized for tanning without producing the UVC, UVB, or UVA2 spectral lines emitted by mercury-vapor tanning lamps commonly used in other tanning devices. UVA1 is closer to blue light, whereas UVA2 is closer to UVB. Since UVA1 is less energetic than UVA2, UVA1 is thought to be less damaging than UVA2, UVB and UVC.
TanThera intends to promote the use of more precise terms to reduce the confusion surrounding ultraviolet light caused by the broad definition of the terms UVC, UVB, and UVA, which have varied in the scientific literature. Within a single range, the effects of different wavelengths can be vastly different, which causes additional confusion. The confusion resulting from the blurring of the specific wavelengths has created on-going debates over health benefits and risks associated with ultraviolet light. TanThera believes that much of the conflicting advice related to ultraviolet light would be resolved if the terms UVC, UVB, and UVA were abandoned in favor of more accurate descriptors.
The term UVC is defined herein as light from 100 nanometer ("nm") to 280 nm. The term UVB is defined herein as light from 280 nm to 320 nm. The term UVA is defined herein as light from 320 nm to 400 nm. UVA is often sub-divided into UVA1 and UVA2. The term UVA1 is defined herein as light with wavelengths from 340 nm to 400 nm. The term UVA2 is defined herein as light with wavelengths from 320 nm to 340 nm.
TanThera is a New York state corporation which has a mission to commercialize UV LED tanning products and services. TanThera is a wholly owned subsidiary of Opthera, Inc., also a New York state corporation, with a mission to commercialize UV LED tanning and phototherapy products and services.
For more information contact:
Peter Fiset, CEO Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211 USA
email: PeterFiset@Opthera.com
###
News Release: November 6th, 2008, Albany, NY.
The article quotes Dr. Frank Rice, Ph.D., of the Center for Neuropharmacology and Nueroscience at Albany Medical College, "I think [t]his delivery system is very well thought out in taking the strategy of producing exactly the wave length[s] of light that one wants..."
For more information contact:
Christopher Macomber, COO
Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211
USA
email: ChrisMacomber@Opthera.com
###
News Release: August 29th, 2008, Albany, NY.
The Opthera, Inc. prototype LED tanning bed has been featured in the August 2008 issue of LD+A which is the magazine of the Illuminating Society of North America. TanThera, Inc. is the wholly owned subsidiary of Opthera, Inc. that is sublicensing enabling technology from Opthera, Inc. in the field of UV LED tanning. WellThera, Inc. is the wholly owned subsidiary of Opthera, Inc, that is licensing from Opthera, Inc. in the field of phototherapy. Both companies are commercializing products that share some common design features that could lead to economies of scale and increased adoption rates with customers.
The chamber incorporates a quiet water cooled heat sink which substantially reduces the noise compared to legacy tanning equipment. The LEDs in the prototype (shown) are blue for full-scale demonstration purposes. Both compact and full-scale functional UV LED prototype devices are currently under development.
For more information contact:
Christopher Macomber, COO
Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211
USA
email: ChrisMacomber@Opthera.com
###
News Release: February 21th, 2008, Albany, NY.
The Union College (Schenectady, NY) affiliated Eliphalet Nott Society together with The Union Business Network are holding a business forum and reception on Tuesday, March 4, 2008 from 6:00pm to 9:00pm at the The Cornell Club, 6 East 44th Street, New York City, NY, USA. Cocktails and hors d'oeuvres will be severed. Cost: $35 per person. Click here for more details and to RSVP.
The forum includes a presentation titled 'At the Nexus of Technology, Medicine and Entrepreneurship: Bringing New Biomedical Devices to Market'. The presentation is by Ting Pau Oei, of L Capital Partners, and Chris Macomber, COO of Opthera Inc. Ting Pau Oei (Class of '68) will share his 30 years of experience on the complexities of identifying the right products and the viability of bringing them to market. Entrepreneur Chris Macomber (Class of '05) will join Mr. Oei and pitch Opthera Inc's potential for rapid growth resulting from the commercialization of novel improvements to indoor-tanning and phototherapy devices. If time permits, Peter Fiset, CEO of Opthera Inc will provide a technical demonstration, and the pioneer of SLE phototherapy, Dr. Hugh McGrath, Prof. of Medicine Tulane University (New Orleans, LA), will provide a research perspective.
For more information contact:
Christopher Macomber, COO
Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211
USA
email: ChrisMacomber@Opthera.com
###
News
Release: November
26th, 2007, Albany, NY.
A presentation by Christopher Macomber, COO of Opthera, Inc. will be given on Thursday, November 29, 2007 at 3PM in the Huyck Auditorium located at the Albany Medical College, 43 New Scotland Avenue, Albany NY, 12208.
Presentation Title:
Partnering for Advances In Systemic Lupus Erythematosus (SLE) Phototherapies.
Presentation Abstract:
Until a few years ago, it was commonly believed that all ultraviolet (UV) light was harmful to SLE patients. However, recent peer-reviewed research has identified the narrow range of UVA-1 (340nm - 400nm) that has both beneficial and therapeutic effects on the treatment of SLE. Opthera, Inc. is a biotechnology company that is applying solid-state-lighting techniques to further improve and commercialize SLE phototherapies and broaden the techniques to related diseases. The UV light-emitting diode (UV LED) represents one of the major developments in the field solid-state lighting that has allowed for the improvement of various medical therapies. LEDs have advantages over the legacy light sources in spectral, temporal, and spatial specificities. Research opportunities currently exist in the effort to bring the UVA-1 SLE phototherapy though the various stages of FDA approval. Long-term opportunities also exist in the further application of biophotonics and nano-scale engineering to SLE and other disease indications.
For more information contact:
Christopher Macomber, COO
Opthera, Inc.
5 Upper Loudon Road
Loudonville, NY 12211
USA
email: ChrisMacomber@Opthera.com
###
All rights reserved